![]() ![]() The company posted first-half sales of €449 million ($490 million), a 13% increase from a year ago. Schott Pharma published its first earnings statement on Thursday, showing its margin rose to 29% in the first half of 2023, above the 28% it said it posted for the same period in 2022. Any decision depends on market conditions in the second half of 2023,” Reisse said, adding that the environment for an IPO is “relatively stable at the moment.” It may now target a lower figure to price in an IPO discount amid tougher markets, the people said. ![]() Bloomberg News previously reported Schott Pharma could seek a valuation of about $4 billion. Reisse declined to comment on a potential valuation of the unit. Speaking in an interview with Bloomberg, Schott Pharma Chief Executive Officer Andreas Reisse said the company’s parent was monitoring market developments. The division manufactures vials used in mRNA vaccines like the coronavirus inoculations produced by BioNTech SE and Moderna Inc, among other products.ĭeliberations are ongoing, and the timing of the potential offering could change, the people said.Ī spokeswoman for Schott declined to comment on the timing of a share sale. The company plans to start meeting analysts about the proposed offering in July, the people said, declining to be named discussing private information. Note: Some sections may be missing if data is unavailable for the company.(Bloomberg) - Schott AG plans to list its specialty medical-glassware division as soon as September, according to people familiar with the matter, paving the way for one of the biggest German initial public offerings this year. Stay up to date on Schott AGs business structure, strategy and prospects. Support sales activities by understanding your customers' businesses better. Track strategic initiatives of the company and latest corporate news and actions.Īssess Schott AG as a prospective partner, vendor or supplier. Gain understanding of Schott AG and the factors that influence its strategies. Large number of easy-to-grasp charts and graphs that present important data and key trends News about Schott AG, such as business expansion, restructuring, and contract wins Schott is headquartered in Mainz, Germany.ĭetailed information on Schott AG required for business and competitor intelligence needsĪ study of the major internal and external factors affecting Schott AG in the form of a SWOT analysisĪn in-depth view of the business model of Schott AG including a breakdown and examination of key business segments Its operations are spread across in Europe, Asia, the Middle East and Africa, North America and South America. The company's products find application in home appliance, automotive, electronics, pharma, life science, aviation and optical industries. It’s product portfolio include advanced optics, pharmaceutical systems, electronic packaging products, lighting and imaging solutions and flat glass, among others. The company offers a broad portfolio of special glass, specialty materials, components and systems. It develops and manufactures specialty glass and glass-ceramics. Schott AG (Schott), a subsidiary of Carl Zeiss Stiftung AG, is a technology group. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360Ëš view of the company. Schott AG – Company Profile & SWOT Analysis, is a source of comprehensive company data and information. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |